Wednesday July 3, 2024				
07:30	Registration			
08:45	Opening Ceremony			
09:05	Inaugural Lecture Toward Universal Druggability (PL01) Prof. Gregory L. VERDINE (CO-FOUNDER, PRESIDENT AND CEO LIFEMINE THERAPEUTICS, Cambridge, MA, United States)			
09:40	Session 1 - RNA Binding Molecules			
09:40	Tools and Tactics for Targeting RNA with Small Molecules (PL02) Dr Jay SCHNEEKLOTH (NATIONAL CANCER INSTITUTE, Frederick, United States)			
10:15	Small-Molecule Inhibitors of RNA-binding Proteins Regulating m6A RNA Methylation (SL01) Dr Peng WU (MAX-PLANCK-INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)			
10:35	Coffee Break & Exhibition			
	Session 2 - Breakthroughs in Deep Learning, CryoEM and their Impact on Drug Discovery			
11:10	Modern Modelling Techniques to Aid Structure-Based Drug Design (PL03) Dr Massimiliano BONOMI (INSTITUT PASTEUR, Paris, France)			
11:45	Cryo-EM at Astrazeneca: Enabling SBDD in Challenging Multiprotein Targets (SL02) Dr Taiana MAIA DE OLIVEIRA (ASTRAZENECA PLC, Cambridge, United Kingdom)			
12:05	Lunch, Networking & Exhibition			
12:45	Company Workshop by Schrödinger			
13:00	Poster session			
14:30	Session 3 - New Modalities for Drug Discovery			
14:30	New Modalities Enabling Target Validation (SL03) Dr Werngard CZECHTIZKY (ASTRAZENECA, Mölndal, Sweden)			
14:50	Title to be announced (PL04)			

https://www.rict2024.org/ Page 1/5

ŀ	Prof. Akane KAWAMURA	
((NEWCASTLE UNIVERSITY, Newca	astle, United Kingdom

15:25 Molecular Switches for Gene Control (PL05)

Prof. Olalla VÁZQUEZ (PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany)

16:00 Coffee Break & Exhibition

Session 4 - Chemistry in Living Systems, Chemical Biology, Including Druggability Assessment

16:35 Gut Feeling: Illuminating Atypical Stress-sensing Mechanisms in the Gut Empowers New Therapeutic Opportunities (PL06)

Prof. Yimon AYE (ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

17:10 Exploring PTM Chemical Biology for Drug Discovery (PL07)

Prof. Edward TATE (IMPERIAL COLLEGE LONDON, London, United Kingdom)

17:45 Induced-Volatolomics, a New Research Field in Chemical Biology (SL04)

Dr Pauline POINOT (UNIVERSITY OF POITIERS, Poitiers, France)

18:05 Welcome Drink

19:30 End of the Day

https://www.rict2024.org/ Page 2/5

Thursday July 4, 2024

Session 5: Recent Trends in Neurodegenerative Diseases Drug Development

08:45 Toward a Holistic Drug Discovery Approach - How Chemical Biology & Novel Technologies Support the Identification & Development of Drug Candidates (PL08)

Dr Uwe GRETHER

(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

09:20 Title to be announced (PL09)

Dr Angela MACKAY

(NOVARTIS PHARMA AG, Basel, Switzerland)

09:55 Design, Synthesis and Evaluation of PET Tracers Targeting alpha-Synuclein, a Rational Approach (PL10)

Prof. Bert WINDHORST

(VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands)

10:30 Coffee Break & Exhibition

Session 6 - Induced Proximity Including Degraders

11:05 How Degraders Work: Molecular Recognition and Design Principles (PL11)

Prof. Alessio CIULLI

(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

11:40 Expanding the Chemical Toolbox of E3 Ligase Ligands for PROTAC Design (PL12)

Prof. Michael GUTSCHOW (UNIVERSITY OF BONN, Bonn, Germany)

12:15 Discovery of Novel Small Molecules Binders of Soluble Mutant HTT & Derivatization into PROTACs (SL05)

Dr Geoffrey SCHWERTZ

(UCB BIOPHARMA, Braine l'Alleud, Belgium)

12:35 Lunch, Networking & Exhibition

Career Session

13:15 Company Workshop by WuXi AppTec

13:45 Poster Session

Session 7 - Next Generation Cancer Therapeutics

15:15 Advancements in Drug-like Cyclic Peptides: A Pathway to Orally Available KRAS Inhibitor (PL13)

Dr Satoshi HASHIMOTO

(CHUGAI PHARMACEUTICAL, Kanagawa, Japan)

15:50 Discovering Novel Inhibitors of Wild-type and Acquired Drug-resistant Mutant Forms of c-MET (SL06)

Dr Gavin W. COLLIE

(ASTRAZENECA, Cambridge, United Kingdom)

https://www.rict2024.org/ Page 3/5

16:10	Session 8 - First Disclosures of Clinical Candidates and Cases Studies
16:10	The Discovery of a GPCR Antagonist as Clinical Candidate for Autoimmune Diseases (PL14) Dr Emmanuel MEYER (UNIVERSITY OF BASEL, Basel, Switzerland)
16:45	Coffee Break & Exhibition
17:20	Galapagos Award For Drug Discovery Chemistry (PL15)
18:05	End of the Day
20:00	Symposium Banquet (subject to prior registration)

https://www.rict2024.org/ Page 4/5

Friday	'July	5.	2024

08:45	Session 9 - Enabling Technologies
08:45	Synthetic and Medicinal Chemistry for Biologics (PL16) Prof. Jeffrey BODE (ETH ZURICH, Zürich, Switzerland)
09:20	Recent Advances in DNA-Encoded Library Technologies at GSK (PL17) Dr Lisa MARCAURELLE (GSK, Cambridge, United States)
09:55	Coffee Break & Exhibition
10:30	Vaccines, Antibody Therapies and Diagnostics Based on Synthetic Carbohydrates (PL18) Prof. Peter H. SEEBERGER (MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)
11:05	Evotec Prize for Excellence in Molecular Design (PL19)
11:50	Closing Ceremony
12:20	End of the Symposium

https://www.rict2024.org/ Page 5/5